Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: A randomized controlled trial

JAMA

Volumn 305, Issue 14, 2011, Pages 1432-1440

  Launay, Odile ^a,b,c   Van Der Vliet, Diane ^b,c,k   Rosenberg, Arielle R ^a,b   Michel, Marie Louise ^b,d   Piroth, Lionel ^e   Rey, David ^f   Colin De Verdière, Nathalie ^g   Slama, Laurence ^h   Martin, Karine ^c   Lortholary, Olivier ^a,i   Carrat, Fabrice ^c,j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔPITAL TENON   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k SANOFI PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CONTROLLED STUDY; CYTOLYSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINEMIA; IMMUNOGENICITY; INJECTION SITE DISCOLORATION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTIGO; VOMITING;

EID: 79953847179     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.351     Document Type: Article

References (27)

1. Konopnicki D, Mocroft A, de Wit S, et al; Euro-SIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593-601. (Pubitemid 40543982)
2. Thio CL, Seaberg EC, Skolasky R Jr, et al; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349): 1921-1926. (Pubitemid 35472132)
3. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003; 188(4):571-577. (Pubitemid 37011810)
4. Alberti A, Clumeck N, Collins S, et al; ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42(5): 615-624.
5. Mast EE, Weinbaum CM, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1-33.
6. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902-2908. (Pubitemid 40386492)
7. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2008;19(9):600-604.
8. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005; 41(7):1045-1048. (Pubitemid 41368231)
9. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti- HBs response rate in HIV-infected patients: effects on HIV-1 viral load. Vaccine. 2000;18(13):1161-1165. (Pubitemid 30001829)
10. Tedaldi EM, Baker RK, Moorman AC, et al; HIV Outpatient Study (HOPS) Investigators. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38(10): 1478-1484. (Pubitemid 38678612)
11. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336(3):196-204. (Pubitemid 27034966)
12. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis. 2008; 46(8):1310-1314. (Pubitemid 351589919)
13. Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE. Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther. 2006; 3:9.
14. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine. 2009;27(1):17-22.
15. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A prospective open study of the efficacy of highdose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis. 2008; 197(2):292-294. (Pubitemid 351263450)
16. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis. 2006;6:65.
17. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA (naïve) and CD45RO (memory) subsets in HIV-1-infected subjects. Vaccine. 2006; 24(49-50):7124-7128. (Pubitemid 46107206)
18. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Metaanalysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006;24 (3):497-506. (Pubitemid 44051325)
19. Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000; 31(1):230-234. (Pubitemid 30033712)
20. Hadler SC, Francis DP, Maynard JE, et al. Longterm immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986; 315(4):209-214. (Pubitemid 16097121)
21. Potsch DV, Oliveira ML, Ginuíno C, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28(6):1447-1450.
22. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin Liver Dis. 2004;8(2):283-300. (Pubitemid 38748605)
23. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine. 1995;13(5):443-447.
24. Fernandes SJ, Slhessarenko N, Souto FJ. Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine. 2008;26(8):1032-1037.
25. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197-3208.
26. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2010.MMWRMorb Mortal Wkly Rep. 2010; 59(1):1-4. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm. Accessed January 22, 2011.
27. Yeni P. French HIV guidelines for the use of antiretroviral agents in HIV-1-infected patients in the context of routine clinical practice. http://www.sante.gouv.fr/IMG/pdf/Rapport-2010-sur-la-prise-en-charge-medicale- des-personnes-infectees-par-le-VIH-sous-la-direction-du-Pr-Patrick-Yeni .pdf. Accessed February 28, 2011.